NCT02856100已完成不适用
Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2016年8月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Change in number of metastatic lesions detected on 18F-DCFPyL PET/CT
研究概览
简要总结
We intend to validate 18F-DCFPyL for imaging patients with metastatic, castrate-resistant PCa (CRPC), so that it may be used to full advantage in supporting existing and emerging therapies for a spectrum of patients suffering from PCa. In this study we will image patients with CRPC undergoing second-line anti-androgen therapy (enzalutamide or abiraterone) using 18F-DCFPyL-PET/CT for detection of metastases and therapeutic monitoring, with correlation to standard-of-care conventional imaging modalities (CIM) (CT, bone scan) and clinical follow-up.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent
- •Age ≥ 18 years and male
- •Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
- •Patients starting abiraterone (but naïve to enzalutamide) or starting enzalutamide (but naïve to abiraterone)
- •Prior docetaxel-based chemotherapy is permitted but not required
- •Documented metastatic prostate cancer progression as assessed by the treating oncologist with either one or both of the following:
- •Rising PSA over a minimum 1-week interval
- •Radiographic progression in soft tissue and/or bone
- •Ongoing androgen deprivation with serum testosterone < 50 ng/dL (< 1.7 nM)
- •Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
- •Hemoglobin ≥ 90 g/L independent of transfusion
- •Platelet count ≥ 100,000/μL
- •Serum albumin ≥ 30 g/L
- •Serum creatinine < 1.5 x ULN or a calculated creatinine clearance ≥ 60 mL/min
- •Serum potassium ≥ 3.5 mmol/L
排除标准
- •Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
- •Abnormal liver functions consisting of any of the following:
- •Serum bilirubin ≥ 1.5 x ULN (except for patients with documented Gilbert's disease)
- •AST or ALT ≥ 2.5 x ULN, (for patients with known liver metastasis, AST or ALT ≤ 5 x ULN is allowed)
- •Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg)
- •Active or symptomatic viral hepatitis or chronic liver disease
- •History of pituitary or adrenal dysfunction
- •Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease or cardiac ejection fraction measurement of < 50 % at baseline
- •Other malignancy, except non-melanoma skin cancer, with a ≥ 30% probability of recurrence within 12 months
- •Known brain metastasis
- •History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of orally administered hormonal agents.
- •Acute toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to a NCI CTCAE (version 4.0) grade of ≤ 1; chemotherapy-induced alopecia and grade 2 peripheral neuropathy are allowed
- •Current enrollment in an investigational drug or device study, or participation in such a study within 30 days of first administration of the hormonal agent.
- •Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study
- •Not willing to comply with the procedural requirements of this protocol
- •Patients who have partners of childbearing potential who are not willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 13 weeks after last study drug administration
- •Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study
研究组 & 干预措施
Patients with CRPC, evidence of metastases, planned treatment
干预措施: 18F DCFPyL- Radiopharmaceutical (Drug)
结局指标
主要结局
Change in number of metastatic lesions detected on 18F-DCFPyL PET/CT
时间窗: up to 2 years
Change in number of metastatic lesions detected from baseline standard of care conventional imaging (CT and Bone Scan) to 18F-DCFPyL PET/CT at 8-12 weeks post- anti-androgen therapy (standard of care)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
PSMA-based 18F-DCFPyL PET/CT: Evaluating Its Application in Real LifeProstate CancerNCT03609736Grand River Hospital12
Unknown
2 期
18F-DCFPyL PET-CT Scan and Prostate CancerProstate Cancer AdenocarcinomaNCT03852654Lida Jafari170
进行中（未招募）
2 期
Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.Prostate CancerNCT04655365CHU de Quebec-Universite Laval50
已完成
1 期
Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate CancerMetastatic Prostate CancerNCT01815515Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins22
No Longer Available
不适用
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate CancerProstate AdenocarcinomaPSA Level Greater Than 0.2PSA Level Greater Than or Equal to TwoPSA ProgressionRecurrent Prostate CarcinomaNCT03501940Andrei Iagaru